A Wesley Burks1, Lucien F Harthoorn2, Marleen T J Van Ampting2,3, Manon M Oude Nijhuis2, Jane E Langford3, Harm Wopereis2,4, Steven B Goldberg5, Peck Y Ong6, Brandon J Essink7, Robert B Scott8, Bryan M Harvey9. 1. University of North Carolina, Chapel Hill, NC, USA. 2. Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands. 3. Nutricia Advanced Medical Nutrition, Liverpool, UK. 4. Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands. 5. Visions Clinical Research, Tucson, AZ, USA. 6. Children's Hospital Los Angeles/University of Southern California, Los Angeles, CA, USA. 7. Meridian Clinical Research, Omaha, NE, USA. 8. Asheboro Research Associates, Asheboro, NC, USA. 9. Children's Investigational Research Program, LLC (CHIRP), Bentonville, AR, USA.
Abstract
BACKGROUND:Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires diets that are not only hypoallergenic but also support adequate growth in this population. This study assessed growth of CMA infants when using a new amino acid-based formula (AAF) with prebiotics and probiotics (synbiotics) and evaluated its safety in the intended population. METHODS: In a prospective, randomized, double-blind controlled study, full-term infants with diagnosed CMA received either an AAF (control; n = 56) or AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V) (test; n = 54) for 16 wk. Primary outcome was growth, measured as weight, length and head circumference. Secondary outcomes included allergic symptoms and stool characteristics. RESULTS: Average age (±SD) of infants at inclusion was 4.5 ± 2.4 months. Both formulas equally supported growth according to WHO 2006 growth charts and resulted in similar increases of weight, length and head circumference. At week 16, differences (90% CI) in Z-scores (test-control) were as follows: weight 0.147 (-0.10; 0.39, p = 0.32), length -0.299 (-0.69; 0.09, p = 0.21) and head circumference 0.152 (-0.15; 0.45, p = 0.40). Weight-for-age and length-for-age Z-scores were not significantly different between the test and control groups. Both formulas were well tolerated and reduced allergic symptoms; the number of adverse events was not different between the groups. CONCLUSIONS: This is the first study that shows that an AAF with a specific synbiotic blend, suitable for CMA infants, supports normal growth and growth similar to the AAF without synbiotics. This clinical trial is registered as NCT00664768.
RCT Entities:
BACKGROUND:Children with cow's milk allergy (CMA) are at risk for inadequate nutritional intake and growth. Dietary management of CMA, therefore, requires diets that are not only hypoallergenic but also support adequate growth in this population. This study assessed growth of CMA infants when using a new amino acid-based formula (AAF) with prebiotics and probiotics (synbiotics) and evaluated its safety in the intended population. METHODS: In a prospective, randomized, double-blind controlled study, full-term infants with diagnosed CMA received either an AAF (control; n = 56) or AAF with synbiotics (oligofructose, long-chain inulin, acidic oligosaccharides, Bifidobacterium breve M-16V) (test; n = 54) for 16 wk. Primary outcome was growth, measured as weight, length and head circumference. Secondary outcomes included allergic symptoms and stool characteristics. RESULTS: Average age (±SD) of infants at inclusion was 4.5 ± 2.4 months. Both formulas equally supported growth according to WHO 2006 growth charts and resulted in similar increases of weight, length and head circumference. At week 16, differences (90% CI) in Z-scores (test-control) were as follows: weight 0.147 (-0.10; 0.39, p = 0.32), length -0.299 (-0.69; 0.09, p = 0.21) and head circumference 0.152 (-0.15; 0.45, p = 0.40). Weight-for-age and length-for-age Z-scores were not significantly different between the test and control groups. Both formulas were well tolerated and reduced allergic symptoms; the number of adverse events was not different between the groups. CONCLUSIONS: This is the first study that shows that an AAF with a specific synbiotic blend, suitable for CMA infants, supports normal growth and growth similar to the AAF without synbiotics. This clinical trial is registered as NCT00664768.
Authors: Betty C A M van Esch; Suzanne Abbring; Mara A P Diks; Gemma M Dingjan; Lucien F Harthoorn; A Paul Vos; Johan Garssen Journal: Immun Inflamm Dis Date: 2016-03-24
Authors: Atanaska I Kostadinova; Laura A P M Meulenbroek; Betty C A M van Esch; Gerard A Hofman; Johan Garssen; Linette E M Willemsen; Léon M J Knippels Journal: Front Immunol Date: 2017-01-12 Impact factor: 7.561
Authors: Bryan M Harvey; Simone R B M Eussen; Lucien F Harthoorn; A Wesley Burks Journal: J Pediatr Gastroenterol Nutr Date: 2017-09 Impact factor: 2.839
Authors: Atanaska I Kostadinova; Alba Pablos-Tanarro; Mara A P Diks; Betty C A M van Esch; Johan Garssen; Léon M J Knippels; Linette E M Willemsen Journal: Front Immunol Date: 2017-10-23 Impact factor: 7.561
Authors: Adam T Fox; Harm Wopereis; Marleen T J Van Ampting; Manon M Oude Nijhuis; Assad M Butt; Diego G Peroni; Yvan Vandenplas; David C A Candy; Neil Shah; Christina E West; Johan Garssen; Lucien F Harthoorn; Jan Knol; Louise J Michaelis Journal: Clin Transl Allergy Date: 2019-01-15 Impact factor: 5.871
Authors: Harm Wopereis; Marleen T J van Ampting; Aysun Cetinyurek-Yavuz; Rob Slump; David C A Candy; Assad M Butt; Diego G Peroni; Yvan Vandenplas; Adam T Fox; Neil Shah; Guus Roeselers; Lucien F Harthoorn; Louise J Michaelis; Jan Knol; Christina E West Journal: Clin Transl Allergy Date: 2019-05-31 Impact factor: 5.871
Authors: David C A Candy; Marleen T J Van Ampting; Manon M Oude Nijhuis; Harm Wopereis; Assad M Butt; Diego G Peroni; Yvan Vandenplas; Adam T Fox; Neil Shah; Christina E West; Johan Garssen; Lucien F Harthoorn; Jan Knol; Louise J Michaelis Journal: Pediatr Res Date: 2017-12-06 Impact factor: 3.756